UPDATE 2-India Dr Reddy's Q2 net doubles, keeps FY10 f'cast
* Net profit 2.17 bln rupees vs 1.05 bln year ago
* CEO says will not comment on Glaxo stake buy reports
* Maintains FY2009/10 revenue growth target of 10 percent
* Sales in German unit Betapharm falls on price pressure
* Shares end 6.2 percent higher in flat Mumbai market (Adds CEO comments, byline, updates share price)
By Sumeet Chatterjee
BANGALORE, Oct 23 (Reuters) - Dr Reddy's Laboratories (REDY.BO: Quote, Profile, Research), India's second-largest drug maker by sales, beats forecasts by more than doubling quarterly net profit and maintained its full-year forecast on the launch of new generics, sending its shares up more than 6 percent.
Chief Executive G.V. Prasad declined to comment on reports that U.K.-based GlaxoSmithKline (GSK.L: Quote, Profile, Research) has emerged as the frontrunner for a phased buy in the drugmaker. [ID:nBOM410702]
"We cannot comment on speculative news," Prasad told Reuters. Continued...
Economy seen growing at 7.2 pct in FY10 - govt
The forecast reinforces the possibility that the government may start to unwind its fiscal stimulus in the budget. Full Article
Greek crisis sets euro zone enlargement back
The Greek debt crisis has dealt a setback to prospects of enlarging the euro zone by highlighting the difficulties of managing the single currency area. Full Article
India
US
UK
